Research and Development Investment: Verona Pharma plc vs Soleno Therapeutics, Inc.

Biotech R&D: Verona vs. Soleno's Decade of Innovation

__timestampSoleno Therapeutics, Inc.Verona Pharma plc
Wednesday, January 1, 201422422164101058
Thursday, January 1, 2015453624410763215
Friday, January 1, 201651848035579049
Sunday, January 1, 2017306874232051299
Monday, January 1, 2018717800024482286
Tuesday, January 1, 20191626700043892589
Wednesday, January 1, 20202319100044505000
Friday, January 1, 20212145300079406000
Saturday, January 1, 20221526500049283000
Sunday, January 1, 20232518900017282730
Loading chart...

Unleashing insights

A Decade of Innovation: R&D Investments in Biotech

In the ever-evolving world of biotechnology, research and development (R&D) investments are the lifeblood of innovation. Over the past decade, Verona Pharma plc and Soleno Therapeutics, Inc. have demonstrated contrasting strategies in their R&D expenditures. From 2014 to 2023, Verona Pharma's R&D spending surged by approximately 320%, peaking in 2021 with a remarkable 79 million USD. This reflects their aggressive pursuit of groundbreaking respiratory therapies. Meanwhile, Soleno Therapeutics, focusing on rare diseases, saw a more modest increase of around 1,000% in the same period, with a notable spike in 2023. This divergence highlights the varied approaches within the biotech sector, where Verona's consistent high investment contrasts with Soleno's strategic spikes. As these companies continue to innovate, their R&D investments will undoubtedly shape the future of healthcare, offering hope for new treatments and cures.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025